A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder

The Journal of Clinical Psychiatry
Eduard VietaFrancesc Colom

Abstract

To conduct the first randomized, controlled trial assessing the prophylactic efficacy of gabapentin in bipolar disorder. We conducted a 1-year, double-blind, randomized, comparative, placebo-controlled, parallel-group, multicenter study. As this was a pure prophylactic trial, only euthymic bipolar I and II patients (DSM-IV) were randomly assigned in a 1:1 ratio to gabapentin (N = 13) or placebo (N = 12) added to the current treatment (lithium, valproate, carbamazepine, or any combination but not antipsychotics or antidepressants). Subjects participated in the study for 12 months. The primary efficacy parameter was the Clinical Global Impressions scale for Bipolar Illness, Modified (CGI-BP-M), which was assessed at all visits. Other assessments were the Young Mania Rating Scale (YMRS), Hamilton Rating Scale for Depression (HAM-D), Hamilton Rating Scale for Anxiety (HAM-A), Pittsburgh Sleep Quality Index (PSQI), and the systematic collection of reported adverse events. Data were collected from May 1999 to February 2004. The change from baseline to month 12 in mean CGI-BP-M scores between groups was statistically significant (p = .0046). Mean score change from baseline to endpoint in the gabapentin group was -2.1, and the mean sco...Continue Reading

Citations

May 25, 2012·European Archives of Psychiatry and Clinical Neuroscience·Konstantinos N FountoulakisEduard Vieta
Nov 13, 2009·The New England Journal of Medicine·S Swaroop VedulaKay Dickersin
May 19, 2011·Clinical Neuropharmacology·Toshiaki EgashiraTsukasa Koyama
Jun 15, 2013·BMJ : British Medical Journal·Peter DoshiTom Jefferson
Oct 11, 2007·Annals of General Psychiatry·Konstantinos N FountoulakisGeorge S Kaprinis
Jul 17, 2007·CNS Drugs·Ana González-PintoCristina González Gómez
Oct 23, 2009·CNS Drugs·Marcia Kauer-Sant'AnnaEduard Vieta
May 4, 2010·Journal of Mental Health·Heinz C R Grunze
Feb 16, 2016·The Psychiatric Clinics of North America·Robert M Post
Jun 7, 2013·Expert Review of Neurotherapeutics·Marco Mula
Sep 12, 2015·Expert Opinion on Drug Safety·Eva Maria PichlerMoritz Muehlbacher
Feb 5, 2016·Journal of Affective Disorders·Kristine Kahr NilssonKrista Nielsen Straarup
Apr 1, 2010·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Hance ClarkeJoel Katz
Feb 5, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·A MontoyaM Ferrin
May 5, 2009·General Hospital Psychiatry·John W WilliamsLynn Whitener
Feb 8, 2008·Schizophrenia Research·Caroline Demily, Nicolas Franck
Nov 27, 2007·Journal of Affective Disorders·Konstantinos N FountoulakisGeorge Kaprinis
Sep 13, 2015·Journal of Affective Disorders·P A KudlowV Sharma
May 4, 2011·Early Intervention in Psychiatry·Craig A MacneilPhilippe Conus
Sep 5, 2012·Acta Psychiatrica Scandinavica·K de Barros PellegrinelliR A Moreno
Nov 15, 2011·Journal of Psychiatric and Mental Health Nursing·M CroweP Joyce
Nov 11, 2011·Journal of Psychiatric and Mental Health Nursing·T Stern, J Sin
Sep 12, 2012·Bipolar Disorders·Stephanie McMurrichRoy H Perlis
May 24, 2015·Archives of Psychiatric Nursing·Funda GumusSibel Cakir
Jun 8, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Brisa SoléUNKNOWN CIBERSAM Functional Remediation Group
Mar 14, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Oct 25, 2012·Epilepsy & Behavior : E&B·Piero Perucca, Marco Mula
May 20, 2008·Journal of Affective Disorders·F ColomJ Scott
Sep 15, 2009·Journal of Affective Disorders·Sibel CakirOlcay Yazici
Aug 30, 2008·The International Journal of Neuropsychopharmacology·Konstantinos N Fountoulakis, Eduard Vieta
Jun 1, 2016·Journal of Affective Disorders·Stephanie SalcedoLouisa G Sylvia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here